CEL SCI CORP CVM Cash Flow

Cel sci corp (CVM)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
-9,011	-5,475	-4,848	-12,084	-6,447	1,245	-14,926	-6,014	-4,708	-6,187	-4,993	-4,464	-8,426	3,521	-1,128	-3,861	-8,855	2,332	-9,861	-4,429	-12,556	-7,845	-7,208	-2,444	-13,365	-4,334	-1,699	-4,447	-713	-2,310	-2,566	-835	-8,493	-3,581	-2,317	-3,114	-14,029	-6,250
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
505	446	120	196	161	154	164	177	152	155	156	157	159	159	160	165	167	170	557	50	55	56	572	65	51	56	61	79	90	133	141	109	143	138	96	148	145	141
Share-based payments for services
191	155	167	176	272	238	181	191	115	42	81	38	34	78	132	146	142	329	128	137	110	189	160	189	206	137	90	209	100	54	124	159	205	38	76	5	95	36
Modification of warrants issued to consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	76	-	-	-	-	-	-	-	-	-	-	-	-
Modification of warrants issued for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Equity based compensation
1,780	1,800	1,801	1,521	530	573	549	465	279	1,448	377	325	365	312	849	418	417	427	534	619	892	3,059	2,465	462	520	510	-	-	-	-	-	-	-	-	-	-	-	-
401(k) contributions paid in common stock
-	40	-	-	-	35	36	36	36	35	36	38	38	38	282	-38	-41	-40	288	-42	-40	-40	271	-39	-38	-37	-	-	-	-	-	-	-	-	-	-	-	-
Extension of options issued to employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	36	-	-	-	-
Modification of stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	105	30
Employee option cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	966	504	463	423	837	430	407	335	362
Common stock contributed to 401 (k) plan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39	39	39	38	39	37	38	38	40	37	33
Impairment loss on abandonment of patents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	11	0	0	10	7	16	13	7	9	0	0	0
Loss on retired equipment
-	-	-	-	-	-	-	-	-	-	2	0	0	-1	0	0	0	-0	0	0	0	-0	0	0	0	0	0	0	1	2	0	4	3	1	5	-2	0	-0
(Loss)/gain on derivative instruments
-3,049	766	-	-7,905	-967	5,556	-	-8	1,154	-958	-	790	-48	8,928	-	2,508	-2,593	8,122	-	4,428	-4,782	2,162	-	4,467	-7,132	1,610	-	-	-	-	-	-	-	-	-	-	-	-
Capitalized lease interest
0	0	-	-	30	34	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount
-	-	-	-	-	-	0	933	411	611	896	21	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capitalized lease interest
-	-	-	-	-	-	-293	41	40	43	-350	49	48	51	-396	56	54	57	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss (gain) on derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,079	-3,538	-2,746	-	-	-	-	-	-	-	-
(Increase)/decrease in assets:
Receivables
-28	28	56	-4	-5	10	198	-17	114	-195	-311	267	0	-85	3	56	13	-75	-82	121	-118	74	-13	-54	89	-28	89	-124	-24	143	-132	75	-92	448	-871	244	-288	457
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	185	185	189	-	197	197	176	134	134	135	139	148	148	148	153	161	159	141	166
Prepaid expenses
-10	-86	-126	-85	-30	105	275	-79	-38	-3	426	-55	-123	-96	283	-56	-159	-51	-352	404	12	-133	-231	-70	-66	210	0	314	-257	471	369	30	140	235	-3,721	-62	140	1,913
Supplies used for R&D and manufacturing
-56	123	-246	-6	78	37	71	-2	-14	-27	687	-20	-15	-314	535	-35	-47	-58	86	-151	332	-216	-832	-7	73	330	118	151	-149	247	-11	-4	1	200	-196	104	87	-89
Deposits
-	-	-	-	-	-	0	0	0	150	0	0	4	150	-4	0	0	150	0	0	0	150	0	0	0	-200	0	-400	0	0	-	-	-	-	-	-	-	-
Increase/(decrease) in liabilities:
Accounts payable
-372	-393	-517	-2,077	-754	-734	-554	-1,418	-254	-286	-94	1,300	4,289	-75	-1,310	579	7	-1,666	2,125	1,313	85	457	-180	-23	-166	-380	756	711	41	-192	-132	-5	96	-127	-437	256	22	-629
Accrued expenses
-60	80	-57	-195	210	-127	-656	-40	-67	33	2	424	190	-59	203	-473	279	280	-341	-69	-171	123	177	-130	154	232	-290	352	16	23	-2	2	-14	-84	93	-11,973	12,015	12
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1	0	1	-1	1	-1	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Due to employees
-110	76	-51	-248	113	131	-477	188	208	152	153	-37	123	17	120	-13	-9	-25	-38	67	-0	28	-2	-41	71	-105	118	25	21	20	-6	3	2	-2	17	-58	18	-0
Other liabilities
5	-1	-4	-1	-0	-0	-0	2	-0	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent liability
-	-	-	-	-	-	-	-	-	-	-	-	-0	-1	-1	-0	-0	4	12	-2	-1	-1	-1	-0	-0	-0	-0	-0	-0	0	15	-1	-2	0	-1	-0	-0	-0
Deposits held
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	5	0	0	0	0
Net cash used in operating activities
-3,888	-4,101	-3,887	-4,643	-3,632	-4,157	-4,244	-2,777	-3,754	-2,612	-3,441	-3,125	-2,985	-4,239	-6,863	-5,415	-4,964	-5,837	-5,343	-6,247	-6,803	-5,439	-5,731	-6,022	-5,257	-5,916	-3,406	-3,469	-3,678	-2,994	-3,269	-3,128	-3,180	-2,611	-4,831	-7,176	-4,113	-6,434
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-21	0
Purchases of property and equipment
650	101	6	10	154	6	0	1	0	0	-	-	-	-	0	9	6	14	16	0	39	17	37	39	18	8	8	16	60	16	11	12	14	16	41	78	68	27
Proceeds from sale of equipment
-	4	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Expenditures for patent costs
1	12	42	47	1	66	54	1	0	0	6	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	6	14	10	0	0	28	50	0	76	6	37	1
Net cash used in investing activities
-657	-109	-49	-58	-156	-72	-54	-2	-0	-0	-6	0	-10	0	2	-14	-6	-14	-27	-7	-41	-17	-38	-47	-43	-8	-14	-30	-70	-16	-11	-40	-64	-16	-118	-84	-84	-29
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock
7,867	5,050	0	0	0	0	4,700	-35	4,702	2,425	3,351	1,318	2,139	3,709	4,562	4,599	1,707	10,550	-130	14,872	0	6,405	0	9,143	-94	19,380	-18	0	0	9,807	0	5,122	5,356	3,810	3,936	-1,406	1,406	0
Payments on oblgations under capital leases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Payments of stock issuance costs
159	31	-	10	33	46	-	32	26	35	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the purchase of stock by officers and directors
159	25	-	234	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
1,772	297	2,859	8,352	2,655	649	7,279	2,133	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercises of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	175	-320	749
Payments on obligations under finance lease
198	191	-	-	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,970	1,980	0	0	0	0
Payments on obligations under capital lease
-	-	-	-	-	-	1	1	1	2	1	0	0	2	1	2	2	2	2	2	2	2	2	2	1	2	2	1	1	1	-	-	-	-	-	-	-	-
Net cash provided by financing activities
9,492	5,149	2,895	8,673	2,620	601	12,262	2,064	4,674	2,387	4,584	2,827	2,139	3,707	4,560	4,597	601	10,548	-132	14,870	-2	6,403	-2	9,750	2,412	19,377	-21	-1	-1	9,806	0	5,122	5,051	1,830	-1,365	95	1,086	749
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
4,946	938	-1,040	3,971	-1,168	-3,627	7,963	-715	919	-226	1,136	-297	-856	-531	-2,300	-833	-4,370	4,695	-5,503	8,616	-6,846	947	-5,772	3,680	-2,888	13,452	-3,442	-3,501	-3,750	6,795	-3,281	1,953	1,806	-798	-6,315	-7,165	-3,112	-5,714
Decrease in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,321	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,200	0	2,160	2,400	2,146	0	0	0	0
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	0	0	0
Increase in common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15	-	-	-	-	-	-	-	-	-	-	-	-
Increase in common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-8	0	0	0	0
Increase in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,101	-	0	0	0	0	0	0	-241	0	0	0	0
Decrease in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,117	-	0	0	0	0	0	0	-250	0	0	0	0
Increase in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Decrease in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	0	0	0
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Increase in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1,068	0
Decrease in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Increase in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-55	-	59	59	-236	88	72	-213	0	-	-	-	-
Increase in prepaid services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	16	6	-	-35	97	-55	-	59	59	-236	88	72	-213	0	-	-	-	-
Increase in patent costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	1	8	22	0	-15	15	-65	58	-30	65
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Decrease in derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-141	-61
Increase in additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-141	-61
Increase additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-325	-	-	-	-
Decrease in additional paid in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,006	-17	454	-	-	-	-	-	-	-	-	0	0	0	325	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in additional paid in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Direct offering costs charged to APIC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-84	-	4	-12	0	-	0	4	-4	-	-17	-12	-4
Decrease additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Increase in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	15	-15	-	-58	30	-65
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in current liabilities
22	296	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capitalizable patent costs included in current liabilities
-	-	-	-	-	-	-	53	1	6	-	2	1	6	-	-0	-0	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finance lease obligation included in accounts payable
0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid consulting services paid with issuance of common stock
208	-71	142	-203	119	-36	48	17	112	-16	34	4	-23	-18	16	-53	46	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing costs included in current liabilities
-	76	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property and equipment acquired through capital lease
-	-	-	-	-	-	-	-	-	-	-	0	0	26	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrants issued in connection with public offering
-	-	-	-	-	-	-	-	-	-	-	744	1,605	2,316	-	2,113	0	5,060	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	-	-	-	-
Increase in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	-1	-8	-	-	-	-	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Increase in research and office equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12	-	4	-86	36	0	0	4	-4	34	-17	-12	-4
Decrease (increase) in capital lease obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	-	0	73	-36	0	0	0	0	-	-	-	-
Patent costs purchased with common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	-	-	-	-	-	-	-	-	-	-	-	-
Lease payments included in accounts payable at year end
-	-	-	-	-	-	-	-	-0	0	-0	0	1	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes payable converted into common shares
-	-	-	-	-	-	-	2,110	109	75	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-	-	-	-
(Gain)/loss on derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,204	-956	-	1,763	3,062	-1,946
(Increase) in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-140	23	-23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrant liabilities on the date of issuance reclassed to liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-8,003	0	-460	0	-283	2,283	-7,321	0	0	0	-4,200	0	-2,160	-2,400	-2,146	0	0	0	0
Increase in receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in research and office equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14	-26	23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Decrease in capital lease obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	0	0	1	0	0	0	0	-	-	-	-
Financing costs included in accounts payable at year end
-	-	-	-	-	-	-	-	-	-	-56	-26	40	77	21	22	-19	21	-128	128	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services
-	-	-	-	-	-	-	-	-	-	-610	0	0	305	-57	64	-67	366	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-0	-1	0	0	0	0	-	-	-	-
Total
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-	-
Cash paid for interest
290	295	453	453	453	448	438	440	438	433	475	472	471	469	467	465	463	504	1,844	41	41	41	1,826	41	41	56	29	42	42	41	41	41	76	218	71	41	41	41